Key takeaways
Oral semaglutide is the pill form of semaglutide, the same active ingredient that’s in injectable medications like Ozempic and Wegovy.
Currently, oral semaglutide is only approved for type 2 diabetes as Rybelsus.
Oral semaglutide for weight loss is expected to be approved by the end of 2025.
Clinical trials show that higher-dose oral semaglutide can produce nearly the same amount of weight loss as injectable Wegovy.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Oral semaglutide is the pill form of semaglutide, the same active ingredient that’s in injectable medications like Ozempic and Wegovy.
Currently, oral semaglutide is only approved for type 2 diabetes as Rybelsus.
Oral semaglutide for weight loss is expected to be approved by the end of 2025.
Clinical trials show that higher-dose oral semaglutide can produce nearly the same amount of weight loss as injectable Wegovy.
Semaglutide may be best known as the active ingredient in the injectable medications Ozempic and Wegovy, but it is also available in oral form. Rybelsus is already on the market as a prescription medication for people with type 2 diabetes.
A new oral semaglutide formulation, intended for weight loss, could be approved as soon as the end of 2025. This yet-to-be-approved version will be an oral form of Wegovy, and will come in higher-strength dosages for weight loss.
If you’re interested in semaglutide for weight loss or diabetes, but the idea of needles gives you the willies, oral semaglutide can be a welcome alternative. Read on as we explore what you need to know about oral semaglutide, including how it works, side effects, cost, and more.
What is oral semaglutide?
Oral semaglutide is a daily oral medication that’s approved by the US Food and Drug Administration (FDA) to:
Improve blood sugar control in people with type 2 diabetes, in conjunction with diet and exercise
Reduce the risk of serious cardiovascular problems (such as heart attack, stroke, or death from heart disease) in adults with type 2 diabetes
This version of oral semaglutide is sold under the brand name Rybelsus and manufactured by Novo Nordisk. It’s the only oral semaglutide currently available in the United States.
However, an oral semaglutide for weight loss may be making its way to market soon. In May 2025, Novo Nordisk applied for FDA approval of a pill form of Wegovy.
The potential weight loss medication is currently awaiting FDA approval and may hit pharmacy shelves in early 2026. The brand name “Wegovy pill” has been pitched, but it isn’t confirmed yet.
Types of oral semaglutide: Rybelsus vs. Wegovy
Brand name | Rybelsus | Wegovy pill |
|---|---|---|
FDA approval | Approved in 2019 | Approval pending in late 2025 |
What it treats | Type 2 diabetes (T2D) in adults, along with diet and exercise
Cardiovascular risk reduction in adults with T2D | Weight loss in adults with obesity and overweight |
How it’s taken | Daily, in the morning, at least 30 minutes before food, water, or other medications | Daily, in the morning, at least 30 minutes before food, water, or other medications |
Dosage amounts | Formulation R1: 3 mg, 7 mg, 14 mg Formulation R2: 1.5 mg, 4 mg, 9 mg | 3 mg, 7 mg, 14 mg, 25 mg (based on OASIS 4 trial) |
Common side effects | Nausea, stomach pain, diarrhea, decreased appetite, vomiting, constipation | Nausea, vomiting, constipation, indigestion, diarrhea (based on OASIS 4 trial) |
Cost (without insurance) | $997.58 | Unknown |
How does oral semaglutide work?
Oral semaglutide works similarly to injectable semaglutide. Both versions are glucagon-like peptide-1 receptor agonists (GLP-1s), which mimic a gut hormone produced by your body that’s called — you guessed it — GLP-1.
Like natural GLP-1, semaglutide targets GLP-1 receptors located throughout your gastrointestinal tract, pancreas, and brain to:
Slow down digestion
Encourage the release of insulin after eating
Reduce the amount of glucagon (sugar) that gets released after eating
Send signals of satiety (fullness) to your brain
Together, these effects help control both your blood sugar levels and your appetite. This is why oral semaglutide can be an effective treatment for type 2 diabetes and weight loss.
Can you take oral semaglutide for weight loss?
Yes, you can take oral semaglutide for weight loss. However, since the so-called Wegovy pill is not yet available, it would be an off-label prescription of Rybelsus.
Rybelsus is the only form of oral semaglutide currently available. It is FDA-approved for managing type 2 diabetes — not for weight loss. Still, some people may take Rybelsus off-label for weight loss.
If and when oral Wegovy is approved, it will be the first version of oral semaglutide (as well as the first oral GLP-1) specifically approved for weight loss. It will also have a higher dosage than Rybelsus.
Research on oral semaglutide for weight loss
Oral semaglutide for weight loss (aka the Wegovy pill) is being developed and has yet to be approved. So far, trial results show it can be quite effective for weight loss in people with obesity or overweight:
In an OASIS-4 clinical trial, people who took 25 mg of oral semaglutide daily lost an average of 13.6% of their body weight after 64 weeks (about a year and three months).
In an OASIS-1 clinical trial, people who took 50 mg of oral semaglutide daily lost an average of 15.1% of their body weight after 68 weeks (about a year and four months).
In an early-phase clinical trial that tested whether the drug could reduce calorie intake, people who took 50 mg of oral semaglutide ate about 40% fewer calories on average than those taking a placebo. They also lost nearly 10% of their body weight after five months.
For comparison, research found that taking 2.4 mg of injectable semaglutide weekly caused an average weight loss of 14.9% of body weight after 68 weeks.
Prior to the development of the Wegovy pill, the research on oral semaglutide for weight loss was based on Rybelsus, which is taken in lower doses to manage diabetes.
Since Rybelsus is not approved for weight loss, it hasn’t been as widely studied for that purpose. Even so, these studies found that Rybelsus can produce a modest amount of weight loss in people with type 2 diabetes.
One study found that people lost 6.5 pounds in three months and nearly 9 pounds after six months of taking Rybelsus.
Another study found that about one in three people lost at least 5% of their body weight after a year and a half of taking Rybelsus.
It’s worth noting that these studies of Rybelsus were all conducted in people with type 2 diabetes. These people may also be taking medications that can contribute to weight gain and slow weight loss, such as insulin.
The TL;DR? For now, the only version of oral semaglutide available is the lower-strength Rybelsus, which has been found to produce modest weight loss. However, available research on oral semaglutide for weight loss — the Wegovy pill — has shown this version of the drug to cause significant weight loss — comparable to that of the Wegovy injection.
Potential side effects and risks of oral semaglutide
The most common side effects of oral semaglutide (Rybelsus) include:
Stomach pain
Diarrhea
Decreased appetite
Vomiting
Typically, these gastrointestinal side effects are most common when starting treatment and when increasing your dose.
Other, less common side effects of oral semaglutide include:
Bloating
Upset stomach
Belching
Flatulence
Gastritis (stomach inflammation)
While rare, oral semaglutide can also cause serious side effects, including:
Acute pancreatitis
Diabetic retinopathy complications (diabetes-related vision changes)
Hypoglycemia (low blood sugar) when used with insulin and similar medications
Kidney or gallbladder issues
Severe gastrointestinal reactions
Severe allergic reactions
Pulmonary aspiration during general anesthesia or deep sedation
In animal studies, semaglutide caused thyroid tumors, but it’s unclear if this occurs in humans. For this reason, semaglutide has a boxed warning about a possible risk of thyroid tumors and should not be used by people with a personal or family history of thyroid cancer or a genetic disorder called multiple endocrine neoplasia syndrome type 2 (MEN2).
Oral semaglutide for weight loss (Wegovy pill) appears to cause similar gastrointestinal issues and carry similar risks as other semaglutide medications.
In a phase 3 trial (OASIS 4) comparing oral semaglutide 25 mg to placebo, the most common side effects were:
Nausea
Vomiting
Constipation
Indigestion (dyspepsia)
Diarrhea
Most side effects were mild or moderate and went away without stopping treatment. On average, the participants reported that nausea lasted less than two weeks and vomiting lasted a couple of days.
If the Wegovy pill is approved, its full prescribing information will be published and will include more details about adverse effects.
Oral semaglutide doses
Typically, oral semaglutide doses start low and gradually increase over a period of weeks to months as part of a process called titration (aka escalation). This gives your body time to adjust to the medication and its side effects.
Rybelsus comes in two dosage formulations that aren’t interchangeable: R1 and R2 tablets. They both contain semaglutide and are taken once daily on an empty stomach.
But the new R2 formulation contains different inactive ingredients that help the body absorb semaglutide better. So, even though they contain less semaglutide, the R2 tablets are “bioequivalent” to the original (R1) formulation — meaning both deliver the same levels of semaglutide into the bloodstream.
| R1 formulation | R2 formulation |
|---|---|---|
Dosage strengths | 3 mg, 7 mg, 14 mg | 1.5 mg, 4 mg, 9 mg |
Key differences | Original formulation | Newer formulation that allows more of the drug’s active ingredient (semaglutide) to be absorbed; this allows for lower strengths that are as effective as higher strengths of R1 tablets |
As for the doses of oral semaglutide for weight loss? The standard daily dose for the Wegovy pill will be 25 mg, according to Novo Nordisk.
In studies, people started out with lower doses (3 mg, 7 mg, 14 mg) that gradually increased during the escalation phase. That said, official dosage information and instructions will be released when the medication is approved.
Rx weight loss with Ro
Get access to prescription weight loss medication online
How much does oral semaglutide cost?
Currently, oral semaglutide (Rybelsus) costs $997.58 per month without insurance. The exact amount you pay, however, may vary depending on location, preferred pharmacy, health insurance, and any coupons or discounts.
For example, eligible patients with private or commercial insurance may be able to get Rybelsus for just $10/month as part of the manufacturer’s savings offer. You may also be able to lower the cost of oral semaglutide with the help of pharmacy discounts or coupons available through sites like GoodRx.
The cost of oral semaglutide for weight loss (Wegovy pill) is still unknown since it’s not yet FDA-approved.
Oral semaglutide vs. injectable semaglutide
There are several differences between oral and injectable semaglutide. But a pretty big one is how you take them: one’s a shot and the other’s just a pill you swallow.
Here’s a rough run-down of oral vs. injectable semaglutide:
| Oral semaglutide | Injectable semaglutide |
|---|---|---|
Brand names | Rybelsus | Wegovy, Ozempic |
Approved uses | Control blood sugar levels in adults with type 2 diabetes (T2D)
Reduce cardiovascular risks in adults with T2D
| Wegovy: Weight loss in adults with obesity and overweight Reduce cardiovascular risk in adults with heart disease and obesity or overweight Fatty liver disease
Ozempic: Control blood sugar levels in adults with T2D Cardiovascular risk in adults with T2D and heart disease Kidney decline in adults with T2D and chronic kidney disease |
Frequency | Daily | Weekly |
How it’s taken | In the morning, 30 minutes before any food, water, or other medications | Subcutaneous injection on the same day each week |
Dosage amounts | 1.5 mg–14 mg; varies depending on formulation | Wegovy: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
Ozempic: 0.25 mg, 0.5 mg, 1 mg, 2 mg |
Common side effects | Nausea, stomach pain, diarrhea, decreased appetite, vomiting, constipation | Nausea, diarrhea, vomiting, constipation, stomach pain |
Cost (without insurance) | $997.58 | Wegovy: $1,349.02
Ozempic: $997.58 |
Bottom line
You’ve likely heard about injectable semaglutide — better known as Wegovy and Ozempic — but oral semaglutide is also available in the US. Beyond just featuring the same active ingredient as the headline-making injections, here’s what else you need to know:
Oral semaglutide for diabetes (Rybelsus) is already FDA-approved, while oral semaglutide for weight loss (aka Wegovy pill) may be approved by late 2025.
Higher doses of oral semaglutide have produced weight loss that’s quite similar to — albeit slightly less than — injectable Wegovy.
Oral semaglutide is taken once daily in the morning, at least 30 minutes before food, water, or other medications.
The most common side effects of oral semaglutide include nausea, diarrhea, and stomach pain — all of which typically get better over time.
Rybelsus starts around $1,000 per month without insurance; pricing for oral Wegovy may be announced after FDA approval.
Frequently asked questions (FAQs)
Does oral semaglutide really work?
How well does oral semaglutide work for weight loss? Recent clinical trials found that people with obesity or overweight who took 25 mg of oral semaglutide daily lost an average of 13.6% of their body weight after 64 weeks (about a year and three months).
How long does it take to see results with oral semaglutide for weight loss?
Typically, it doesn’t take long to lose weight on semaglutide, with some people losing about 1–2 pounds in the first month of taking Rybelsus. In clinical trials of oral semaglutide for weight loss (aka the Wegovy pill), people lost 13.6% of their body weight in a little less than a year and a half.
Is oral semaglutide as effective as injectable semaglutide?
Trials of oral semaglutide show that it can be nearly as effective as injectable semaglutide. In recent clinical trials, a daily dose of 25 mg produced an average 13.6% weight loss in 64 weeks. This is slightly less than the average 14.9% weight loss caused by injectable semaglutide in 68 weeks.
How quickly does oral semaglutide start working?
Oral semaglutide can start working about one hour after you take it. But it can take 4–5 weeks to start seeing results. In studies, people have lost 1–3 pounds in the first two months of taking oral semaglutide (Rybelsus), but this can vary. Their blood sugar levels (A1C) improved by about 0.5–1% in the same time period.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
References
Aroda, V. R., Rosenstock, J., Terauchi, Y., et al. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 42(9), 1724–1732. doi: 10.2337/dc19-0749. Retrieved from https://diabetesjournals.org/care/article/42/9/1724/36289/PIONEER-1-Randomized-Clinical-Trial-of-the
Bonora, B. M., Russo, G., Leonetti, F., et al. (2024). Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study. Journal of Endocrinological Investigation, 47(6), 1395–1403. doi: 10.1007/s40618-024-02309-2. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11142994/
Chubb, B., Gupta, P., Gupta, J., et al. (2021). Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis. Diabetes Therapy, 12(5), 1325–1339. doi: 10.1007/s13300-021-01034-w. Retrieved from https://link.springer.com/article/10.1007/s13300-021-01034-w
ClinicalTrials.gov. (2024). A research study looking at how 50 mg semaglutide daily affects food intake and emptying of the stomach in people with obesity. Retrieved Nov. 6, 2025 from https://www.clinicaltrials.gov/study/NCT05236517
ClinicalTrials.gov. (2025). Research study looking at how well semaglutide tablets taken once daily works in people who have a body weight above the healthy range (OASIS 4). Retrieved Nov. 5, 2025 from https://clinicaltrials.gov/study/NCT05564117
ClinicalTrials.gov. (2025). Research study to investigate how well semaglutide tablets taken once daily work in people who are overweight or living with obesity (OASIS 1). Retrieved Nov. 6, 2025 from https://clinicaltrials.gov/study/NCT05035095
Gabe, M. B. N., Breitschaft, A., Knop, F. K., et al. (2024). Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, Obesity & Metabolism, 26(10), 4480–4489. doi: 10.1111/dom.15802. Retrieved from https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15802
Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 402(10403), 705–719. doi: 10.1016/S0140-6736(23)01185-6. Retrieved from https://pubmed.ncbi.nlm.nih.gov/37385278/
Kommu, S. & Whitfield, P. (2024). Semaglutide. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK603723/
Nielsen, M. S., Brøndsted, L., Kankam, M., et al. (2025). A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants. Diabetes Therapy, 16(2), 269–287. doi: 10.1007/s13300-024-01674-8 Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11794934/
Novo Nordisk-a. (2025). Press Release: FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity. Retrieved from https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915988
Novo Nordisk-b. (2025). Press release: Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors.* Retrieved from https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916447
NovoCare-a. (2025). Find out the cost for Ozempic. Retrieved from https://www.novocare.com/diabetes/products/ozempic/explaining-list-price.html
NovoCare-b. (2025). Find out the cost for Rybelsus. Retrieved from https://www.novocare.com/diabetes/products/rybelsus/explaining-list-price.html
NovoCare-c. (2025). What is the list price for Wegovy and will it impact me?. Retrieved from https://www.novocare.com/obesity/products/wegovy/let-us-help/explaining-list-price.html
Rodbard, H. W., Dougherty, T., & Taddei-Allen, P. (2020). Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. The American Journal of Managed Care, 26(16 Suppl), S335–S343. doi: 10.37765/ajmc.2020.88554. Retrieved from https://www.ajmc.com/view/efficacy-of-oral-semaglutide-the-pioneer-clinical-trial-program-and-implications-for-managed-care
U.S. Food and Drug Administration (FDA-b). (2025). Highlights of Prescribing Information: Ozempic (semaglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
U.S. Food and Drug Administration (FDA-a). (2025). Highlights of Prescribing Information: Rybelsus (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024,s028s029lbl.pdf
U.S. Food and Drug Administration (FDA-c). (2025). Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
Volpe, S., Lisco, G., Fanelli, M., et al. (2023). Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study. Frontiers in Endocrinology, 14, 1240263. doi: 10.3389/fendo.2023.1240263. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10534984/
Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England Journal of Medicine, 393(11), 1077–1087. doi: 10.1056/NEJMoa2500969. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40934115/
Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. doi: 10.1056/nejmoa2032183. Retrieved from https://www.nejm.org/doi/10.1056/NEJMoa2032183


















